Dr. Ingmar Gorman is a licensed psychologist specializing in helping individuals navigate anxiety, depression, trauma, substance use, and psychedelic experiences. With a deep understanding of the challenges faced by highly geographically mobile individuals and business leaders—gained through both personal and professional experience—he offers tailored support to clients managing complex lives and transitions. His therapeutic approach blends the latest research with the enduring wisdom of past generations, rooted in evidence-based practices yet open to exploring the unexplained.

As a cofounder of Fluence, a leading psychedelic education company, Dr. Gorman has dedicated his career to training mental health providers worldwide. He brings firsthand experience from his role as site co-principal investigator on an FDA-approved Phase 3 clinical trial of MDMA-Assisted Psychotherapy for PTSD, and as a study therapist in that trial and in a groundbreaking clinical study of psilocybin for treatment-resistant depression. His extensive research and publication record covers classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

Dr. Gorman completed his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He further honed his expertise during an NIH postdoctoral fellowship at New York University. He specializes in individual psychotherapy, psychedelic integration, therapy for clinicians, business therapy, and therapy for expats, third culture kids, and global nomads.